Category: Media

Aurealis Pharma Announces 7.8MCHF Financing to Advance the Chronic Wound Lead Candidate AUP-16 to Diabetic Foot Ulcer Patients under New Brand Aurealis Therapeutics AG

Press release Basel Switzerland, Kuopio Finland – February 8th, 2019.Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland – the Finnish Innovation Funding Agency. The Company also confirmed the de-merger and a … Continued


Read more


Aurealis Pharma Submitted Clinical Trial Application for First-in-Human Phase 1-2A Clinical Study to German Health Authority Paul-Ehrlich-Institute (PEI)

Press Release First-in-Human Study Submission to PEI_15102018 Basel Switzerland, Kuopio Finland – October 15th, 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced today the successful submission of its first Clinical Trial Application to the German Health Authority Paul-Ehrlich-Institute (PEI) for the lead development candidate … Continued


Read more


Aurealis Pharma to Strengthen It´s Board of Directors by Appointing Mr. Iain Buchanan, a Seasoned Biotech and Pharma Industry Executive

Aurealis Pharma Iain Buchanan Press Release 22052018 Basel Switzerland, Kuopio Finland – May 22nd 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that Mr. Iain Buchanan has joined the board of directors of the company as of May 16th 2018. Existing board … Continued


Read more


Aurealis Pharma To Present at the European Wound Management Association (EWMA) Congress 2018 in Krakow, Poland, May 9th – 11th 2018

Aurealis Press Release EWMA congress 2018 30042018 Basel Switzerland, Kuopio Finland – April 30th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CMO Dirk Weber will attend and discuss the company´s progress and clinical development plans for lead development product AUP-16 … Continued


Read more